Showing all 4 results

    CardioMetabolic Profile; Serum

    $510.00

    This advanced test evaluates risk factors for cardiovascular disease (CVD) plus metabolic factors associated with metabolic syndrome and type II diabetes.  In addition to the traditional CVD risk factors, the test includes much more clinically sensitive atherogenic lipoprotein sub-species, the primary apolipoproteins, arterial inflammation and the activity of the lipoprotein- associated phospholipase- A2 (PLAC).  PLAC activity is a very sensitive indicator of active atherogenesis and instability of advanced arterial plaque.  Metabolic syndrome (MetS) is centered around insulin resistance and atherogenic dyslipoproteinemia, and is a risk factor associated with CVD and kidney disease. The test includes cystatin C to better assess glomerular filtration, and 1,5-anhydroglucitol (Glycomark®) that is a better indicator of hyperglycemic episodes than HbA1C.  The primary adipokines associated with insulin sensitivity and hepatic fatty acid metabolism are also addressed.

    Cardiovascular Risk Profile

    $320.00

    Cardiovascular disease (CVD) is associated with more deaths than all cancers—and more deaths in women than breast cancer. This Cardiovascular Risk Profile evaluates a thorough battery of traditional and advanced biomarkers to aid in early detection and modification of risk factors. Doctor’s Data measures the activity of lipoprotein-associated phospholipase-A2 (PLAC), as well as the true LDL culprits; oxidized LDL, small dense LDL and Lp(a), which are higher in CVD patients and correlated with the severity of CVD. A total of thirteen primary and secondary risk factors are evaluated to provide actionable information at a tremendous value.

    Metabolomic Profile

    $230.00

    The Metabolomic Profile provides assessment of the likelihood of Metabolic syndrome in at-risk patients.  The Metabolomic Profile evaluates seven biomarkers that may reflect a patient’s risk of developing Metabolic syndrome, which is identified by a cluster of cardiometabolic risk factors, with insulin resistance and adiposity as its central features. Identification of individuals with metabolic syndrome is important due to its association with an increased risk of and type 2 diabetes mellitus, renal damage and coronary heart disease. Early detection of risk for Metabolic Syndrome is very important because associated symptoms may not be evident until it is well advanced.

    Oxidized LDL

    $140.00

    Plasma levels of Ox-LDL are a sensitive biomarker of atherosclerosis. Elevated Ox-LDL is associated with accelerated atherogenesis, CAD, acute myocardial infarction, and stable and unstable angina. High Ox-LDL has also been associated with metabolic syndrome, impaired glucose tolerance and insulin resistance, and untreated overt hypothyroidism.